MIRM News and Press, Mirum Pharmaceuticals Inc. From 06/23/23

New analysis demonstrates bilirubin normalization in PFIC patients treated with LIVMARLI (maralixibat); the only IBAT inhibitor reported to show this effect Sleep improvement observed in patients with PFIC correlated with maralixibat-driven pruritus reduction (selected as Best of EASL) Ma...

Improvement in pruritus, serum bile acid levels and bilirubin were highly predictive of six-year event-free and transplant-free survival in patients with cholestatic pruritus in Alagille syndrome treated with LIVMARLI Analysis highlights for the first-time potential markers associated w...

Five abstracts accepted for presentation, including data demonstrating bilirubin normalization with LIVMARLI in PFIC Sleep improvement data from MARCH-PFIC study included among ‘Best of EASL’ presentations Maintenance of response in patients with PFIC selected as lat...

2023-06-04 07:30:00 ET Summary Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Shanghai’s Impact Therapeutics out-licensed global rights (ex-China) for t...

Seven oral and poster presentations highlighted during meeting Phase 3 MARCH PFIC data selected as one of highest scoring abstracts and presented during the plenary session RISE study evaluating LIVMARLI in infants with ALGS and PFIC included among highest scoring posters ...

First and only data evaluating IBAT inhibition in treating primary sclerosing cholangitis (PSC) Data provided proof-of-concept for Phase 2b VISTAS study evaluating volixibat, an IBAT inhibitor, in patients with PSC Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced tha...

Seven abstracts accepted including four oral presentations Phase 3 MARCH PFIC data selected as one of highest scoring abstracts and will be presented during the plenary session on May 18 RISE study evaluating LIVMARLI in infants with ALGS or PFIC included among highest scoring pos...

Topline data are expected in second half of 2023. EMBARK will be the first completed randomized study of an IBAT inhibitor for the treatment of biliary atresia. Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced it has completed enrollment of its Phase 2b EMBARK study ...

2023-05-04 17:33:07 ET Mirum Pharmaceuticals press release ( NASDAQ: MIRM ): Q1 Non-GAAP EPS of -$0.80 beats by $0.17 . Revenue of $31.6M (+145.2% Y/Y) beats by $0.81M . Shares -2.33% AH. For further details see: Mirum Pharmaceuticals Non-GAAP EPS...

- $31.6 million total revenue, including net product sales for LIVMARLI ® (maralixibat) oral solution of $29.1 million, for first quarter 2023 - Conference call to provide business updates today, May 4 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) toda...